The company is a pharmaceutical formulations manufacturer with a strong emphasis on innovation, supported by focused research and development. It is steadily expanding its portfolio of specialty formulations and drug-device combination products, primarily targeting regulated international markets, with a particular focus on the United States.Among its peer group of six listed Indian pharmaceutical companies , the company stands out as the only Indian player exclusively focused on regulated markets, underscoring its strategic commitment to high-quality, compliance-driven global operations.Â
Price Band₹0 |
Dates- |
GMP₹0 (-) |
Subscriptions- |
Issue Size₹1,085.00 Crs |
Price Band₹0 |
Listing AtNSE & BSE |
IPO Issue Type100% Book Built Offer |
Fresh Issue₹500.00 Cr (0.00 Shares) |
Offer For Sale₹585.00 Cr (0.00 Shares) |
Total Issue₹1,085.00 Cr (0.00 Shares) |
Face Value₹1 per equity share |
Investor Category | Lot | Shares | Amount | |
---|---|---|---|---|
Retail |
Minimum
1
1
0
Maximum
-
-
-
|
|||
Small HNI |
Minimum
-
-
-
Maximum
-
-
-
|
|||
Big HNI |
Minimum
-
-
-
|
The estimated Grey Market Premium of Rubicon Research IPO is ₹0 per share (-)
Particulars | Allocation |
---|---|
QIB | Not less than 75% of Net Offer |
Big HNIs (NII) | Not more than 10% of Net Offer |
Small HNIs (NII) | Not more than 5% of Net Offer |
Retail | Not more than 15% of Net Offer |
Employee | NA |
Shareholder | NA |
Particulars | Mar-24 | Mar-23 | Mar-22 |
---|---|---|---|
Revenue from Operations | 853.89 | 393.52 | 313.57 |
Profit after Tax | 91.01 | -16.89 | -67.12 |
Net Worth | 385.00 | 286.38 | 305.40 |
Total Borrowing | 396.41 | 317.91 | 169.56 |
Total Assets | 1,109.49 | 749.70 | 559.52 |
NAV per share (in ₹) | 25.31 | 18.83 | 20.08 |
EPS - Basic (in ₹) | 5.98 | -1.11 | -4.41 |
The financial information presented is on a consolidated basis.
KPI | KPI |
---|---|
EBITDA | 19.84% |
PAT | 10.43% |
ROCE | 18.62% |
Name | Shareholding |
---|---|
General Atlantic Singapore RR Pte. Ltd | 57.57 |
Pratibha Pilgaonkar | 4.17 |
Sudhir Dhirendra Pilgaonkar | 4.17 |
Parag Suganchand Sancheti | 0.02 |
Surabhi Parag Sancheti | 8.48 |
Sumant Sudhir Pilgaonkar | 8.46 |
Others | 0.33 |
Total | 83.2 |
Name | Designation |
---|---|
Kumarapuram Gopalakrishnan Ananthakrishnan | Chairman |
Nitin Jajodia | CFO |
Parag Suganchand Sancheti | CEO |
Name: Rubicon Research Limited
Address: MedOne House, B-75, Road No. 33, Wagle Estate, Thane West- 400 604, Maharashtra, India
Number: 022 61414 000
Email: investors@rubicon.co.in
Website: www.rubicon.co.in
Find answers to common questions that come in your mind related to IPO.
Rubicon Research IPO is a Mainboard IPO having an issue size of Rs. ₹1,085.00 Crs. Rubicon Research IPO is priced at ₹0 - ₹0 per share. The issue opens on 12 Jul 25 and closes on 12 Jul 25.
Rubicon Research IPO opens on 12 Jul 25 and closes on 12 Jul 25.
The estimated Grey Market Premium of Rubicon Research IPO is ₹0 per share (-).
The minimum lot size of Rubicon Research IPO is shares & the minimum application amount is Rs. 0.
The allotment date of Rubicon Research IPO is 12 Jul 25.
The listing date of Rubicon Research IPO is 12 Jul 25.
Rubicon Research IPO is subscribed -.
Rubicon Research IPO is priced at ₹0 - ₹0 per share.
Click the allotment link on Rubicon Research IPO page of IPO360.